Sign In
Buy XENE
$53.46
+1.16 (+2.22%)
At Close: Jun 03, 2026
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:42pm, Friday, 02'nd May 2025
VANCOUVER, British Columbia and BOSTON, May 02, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developin
Xenon- A Later Stage Story
03:36am, Friday, 18'th Apr 2025
Xenon's lead asset, azetukalner, shows promise in treating focal onset seizures with positive phase IIb results and upcoming phase III data expected by end of 2025. Azetukalner's unique Kv7 potassium
Xenon Pharmaceuticals Looks Attractive Before Epilepsy Data
04:23pm, Friday, 04'th Apr 2025
Xenon Pharmaceuticals Inc.'s lead asset, azetukalner (XEN1101), shows promising phase 2b results for focal onset seizures (FOS) and is in phase 3 trials for FOS and PGTCS. Despite failing to meet the
Xenon to Showcase Long-Term 36-Month Azetukalner Data at AAN 2025
08:30am, Friday, 04'th Apr 2025
VANCOUVER, British Columbia and BOSTON, April 04, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, develop
Xenon to Present at Stifel 2025 Virtual CNS Forum
04:01pm, Wednesday, 12'th Mar 2025
VANCOUVER, British Columbia and BOSTON, March 12, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, develop
Xenon Q4 Loss Narrower Than Expected, Pipeline Development in Focus
10:40am, Friday, 28'th Feb 2025
XENE reports a narrower-than-expected fourth-quarter 2024 loss. Its development programs for azetukalner in epilepsy and MDD are progressing well.
Xenon Pharmaceuticals Inc. (XENE) Q4 2024 Earnings Call Transcript
11:53pm, Thursday, 27'th Feb 2025
Xenon Pharmaceuticals Inc. (NASDAQ:XENE ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Chad Fugere - Vice President, Investor Relations Ian Mortimer - President a
Xenon Reports Fourth Quarter & Full Year 2024 Financial Results and Business Update
04:01pm, Thursday, 27'th Feb 2025
– Phase 3 topline data from azetukalner FOS epilepsy program planned for H2 2025 in support of NDA filing and potential commercial launch
Xenon to Present at the 45th Annual TD Cowen Healthcare Conference
04:01pm, Tuesday, 25'th Feb 2025
VANCOUVER, British Columbia and BOSTON, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developi
Xenon to Report Q4 and Full Year 2024 Financial Results on February 27, 2025
04:01pm, Thursday, 20'th Feb 2025
VANCOUVER, British Columbia and BOSTON, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developi
XENON Systems Partners with Netris to Deliver Multi-tenant GPU Cloud Networking Solutions for AI/ML Cloud Providers in the Region
12:00pm, Wednesday, 12'th Feb 2025
SANTA CLARA, Calif.--(BUSINESS WIRE)-- #GPU--Netris, an innovative software company specializing in cloud-like network automation and abstraction, is excited to announce a partnership with XENON Syste
Xenon Pharmaceuticals: 2025 Could Be Pivotal For Azetukalner's Epilepsy Potential
01:41am, Thursday, 16'th Jan 2025
Xenon Pharmaceuticals' Azetukalner has good Phase 2 data for MDD using Kv7 potassium channels. This also gives it a good safety profile. The company has robust financials with a runway that should las
Xenon Outlines Key Corporate Milestone Opportunities for 2025
08:30am, Monday, 13'th Jan 2025
– Topline data from the first Phase 3 FOS study anticipated in H2 2025 representing major milestone in support of NDA filing and potential launch of azetukalner
Xenon to Present at the 43rd Annual J.P. Morgan Healthcare Conference
08:30am, Tuesday, 07'th Jan 2025
VANCOUVER, British Columbia and BOSTON, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developi
Xenon Pharmaceuticals (XENE) Up 2.4% Since Last Earnings Report: Can It Continue?
12:36pm, Thursday, 12'th Dec 2024
Xenon Pharmaceuticals (XENE) reported earnings 30 days ago. What's next for the stock?
